entospletinib + vincristine + dexamethasone

A combination therapy comprising **entospletinib** (an oral, selective spleen tyrosine kinase [SYK] inhibitor), **vincristine** (a vinca alkaloid anti-mitotic chemotherapy), and **dexamethasone** (a synthetic glucocorticoid corticosteroid), primarily studied in preclinical and early clinical settings for hematologic malignancies such as acute myeloid leukemia (AML) and diffuse large B-cell lymphoma (DLBCL). Entospletinib inhibits SYK, disrupting B-cell receptor and other signaling pathways, contributing to anti-leukemic effects, while vincristine disrupts microtubule formation, leading to cell cycle arrest, and dexamethasone exerts anti-inflammatory and lympholytic effects. Combining entospletinib with vincristine and/or dexamethasone aims to exploit potential synergistic effects against malignant hematopoietic progenitor cells, especially in AML and some lymphoid neoplasms[2][3].